Drug intelligence / Profile preview

carboplatin + nivolumab + paclitaxel

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of carboplatin (a platinum-based chemotherapy), nivolumab (an anti-PD-1 monoclonal antibody immunotherapy), and paclitaxel (a taxane chemotherapy). This regimen combines traditional cytotoxic chemotherapy with immune checkpoint inhibition to treat various cancers, particularly non-small cell lung cancer (NSCLC). The combination has shown improved efficacy compared to chemotherapy alone in both neoadjuvant and metastatic settings.

Other names: nivolumab plus paclitaxel plus carboplatin

Targets

PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on carboplatin + nivolumab + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + nivolumab + paclitaxel.

Explore the full profile